357 related articles for article (PubMed ID: 28405515)
1. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.
Wei X; Lai Y; Li J; Qin L; Xu Y; Zhao R; Li B; Lin S; Wang S; Wu Q; Liang Q; Peng M; Yu F; Li Y; Zhang X; Wu Y; Liu P; Pei D; Yao Y; Li P
Oncoimmunology; 2017; 6(3):e1284722. PubMed ID: 28405515
[TBL] [Abstract][Full Text] [Related]
2. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract][Full Text] [Related]
3. PSCA is a target of chimeric antigen receptor T cells in gastric cancer.
Wu D; Lv J; Zhao R; Wu Z; Zheng D; Shi J; Lin S; Wang S; Wu Q; Long Y; Li P; Yao Y
Biomark Res; 2020; 8():3. PubMed ID: 32010446
[TBL] [Abstract][Full Text] [Related]
4. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
5. Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.
Ma HY; Das J; Prendergast C; De Jong D; Braumuller B; Paily J; Huang S; Liou C; Giarratana A; Hosseini M; Yeh R; Capaccione KM
Curr Issues Mol Biol; 2023 Nov; 45(11):9019-9038. PubMed ID: 37998743
[TBL] [Abstract][Full Text] [Related]
6. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
7. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
[TBL] [Abstract][Full Text] [Related]
8. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.
Khuisangeam N; Jewmoung S; Thaiwong R; Tudsamran S; Hirankarn N; Suppipat K; Tawinwung S
J Immunol Res; 2022; 2022():2449373. PubMed ID: 36457849
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
[TBL] [Abstract][Full Text] [Related]
10. JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination.
Zhang H; Zhao H; He X; Xi F; Liu J
Cancer Manag Res; 2020; 12():9813-9824. PubMed ID: 33116840
[TBL] [Abstract][Full Text] [Related]
11. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.
Priceman SJ; Gerdts EA; Tilakawardane D; Kennewick KT; Murad JP; Park AK; Jeang B; Yamaguchi Y; Yang X; Urak R; Weng L; Chang WC; Wright S; Pal S; Reiter RE; Wu AM; Brown CE; Forman SJ
Oncoimmunology; 2018; 7(2):e1380764. PubMed ID: 29308300
[TBL] [Abstract][Full Text] [Related]
12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
13. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
Rajabzadeh A; Rahbarizadeh F; Ahmadvand D; Kabir Salmani M; Hamidieh AA
Cell J; 2021 Jan; 22(4):502-513. PubMed ID: 32347044
[TBL] [Abstract][Full Text] [Related]
14. LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer.
Hu Z; Zheng X; Jiao D; Zhou Y; Sun R; Wang B; Tian Z; Wei H
Mol Ther Oncolytics; 2020 Jun; 17():361-370. PubMed ID: 32405534
[TBL] [Abstract][Full Text] [Related]
15. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
[TBL] [Abstract][Full Text] [Related]
16. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
[TBL] [Abstract][Full Text] [Related]
17. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
[TBL] [Abstract][Full Text] [Related]
18. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract][Full Text] [Related]
19. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
